

HR 2438

To amend the Federal Food, Drug, and Cosmetic Act with respect to broader application of Bayesian statistics and adaptive trial designs.

Congress: 114 (2015–2017, Ended)

Chamber: House

Policy Area: Health

Introduced: May 19, 2015

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (May 22, 2015)

Official Text: <https://www.congress.gov/bill/114th-congress/house-bill/2438>

Sponsor

Name: Rep. Collins, Chris [R-NY-27]

Party: Republican • **State:** NY • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	May 22, 2015

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
114 HR 6	Related bill	Jul 13, 2015: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of May 19, 2015)

This bill requires the Food and Drug Administration to issue guidance that addresses using alternative statistical methods, including adaptive trial design and Bayesian methods, in clinical trials and in the development and review of drugs and biological products.

Actions Timeline

- **May 22, 2015:** Referred to the Subcommittee on Health.
- **May 19, 2015:** Introduced in House
- **May 19, 2015:** Referred to the House Committee on Energy and Commerce.